Phaseline

Targets › STING1

STING1 (Stimulator of interferon genes protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Apr 2029.

Key innate immune signaling adapter that promotes the production of type I interferon (IFN-alpha and IFN-beta) in response to the presence of DNA from bacteria and viruses in the cytosol. Innate immune response is triggered by non-CpG double-stranded DNA from viruses and bacteria delivered to the cytoplasm, which induces production of cyclic dinucleotides that bind and activate STING1: STING1 recognizes and binds…. (UniProt, Q86WV6)

Open in Phaseline: the race on STING1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese PLA General HospitalManganese Chloride
cGAS-STING pathway activator
CGAS, STING1Phase 3Ovarian CancerApr 2029

Conditions

Ovarian Cancer (1)

Modalities

mixed (1)

Companies

Chinese PLA General Hospital (1)

Related targets

CGAS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.